This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Practical solutions and case studies to propel all dimensions of diversity and inclusion throughout organizations in life sciences.

3M VP talks remaining innovative and embracing diversity

Share this article

 

At Biotech Week Boston for BWB TV Yolla Levitt, Vice President and General Manager, Separation and Purification, Sciences Division at 3M, told us how collaboration, cross-pollination and diversity are all key to innovation.

 


With the biopharma industry growing how can companies stay at the forefront of innovation?

YL: 'With all the growth that’s happening in this industry, as you’ve mentioned, innovative solutions are very critical for the industry... Change and improve life. At 3M we continue living by founder William McKnight's principles. He started working at 3M in 1907, over one hundred years ago, and he had few principles which are very fundamental to the company. The first one is to hire the right people and you give them the freedom. The second is, if you have a management that is very critical of mistakes, it kills initiative and innovation. And the third one is the 15% innovation culture; any person, especially a scientist or engineer, should spend 15% of the time just working on ideas and innovation. That’s actually how Post-it Notes were created.

When you look at how we come up with innovative solutions, it’s really about: 1) understanding customer pain points and customer needs; really going deep in the insights 2) building on technology platforms 3) collaboration. Collaboration is critical to success... With customer insights you need to look very closely, so when we work with biopharma customers we try to really understand what the pain points are. How can we create more efficiency in the process? How can we intensify the process?'

 

Why do you feel diversity and inclusion are so central to the biopharma industry?

YL:  'I really feel that in today's environment, where the markets are global, our customers are global, this is very critical to the industry.  One of the [BWB Diversity and Inclusion Evening] panelists said it very well. He basically said that having diversity is not just the right thing to do, it's really a business thing to do. If you look at the McKinsey report done in 2015, it said that if you are a company in the upper quartile around women and gender diversity, you're 15% more likely to have a better financial return. That's where the whole business part comes in.

If you look at biopharma and the explosive growth that's happening right now, each company is trying to find the best talent. And the best talent has absolutely nothing to do with what your background or gender. It's about the mind, the thoughts, it' how you come up with innovative ideas. This is an industry that absolutely needs to look at how to build the best teams, no matter the racial or ethnic orientation. It's about best talent. It's about retaining this talent and also making sure that your workforce reflects and resonates with your customer base, which is global.'

You can watch the full interview here or in the video above.

 Related articles:

  1. Diversity and Inclusion a hot topic at Biotech Week Boston
  2. Biotechs must focus on inclusion to heighten diversity
  3. "Achieving diversity and inclusion requires engagement from all of us" - Dr. Joan Reede
  4. While diversity is the acceptance of differences inclusion leverages those differences

 

Share this article

Sign up for Talent, Diversity and Inclusion, Life Sciences email updates

Upcoming event

INCLUSION: Diversity, Equity and Inclusion Summit

21 Sep 2021, Virtual Event
Connect with leaders to talk about diversity and inclusion with practical solutions for propelling all dimensions of diversity throughout your organization
Go to site